References
- Joshi S, Joshi P. Management of type 2 diabetes: Treating targets and strategies. SAPJ 2008; 75(8): 36–43.
- UKPDS 16. Diabetes 1995; 44: 1249–1258.
- JA Rowan, WM Hague, et al. Metformin versus Insulin for the Treatment of Gestational Diabetes. NEJM 2008; (19)358: 2003–2015.
- Buse J. Combining insulin and oral agents. Am J Med 2000; 108(6a): 23S-32S.
- Brown JB et al. Diabetes Care 2004; 27: 1535–1540.
- Goldstein BJ, Miller JL. Contemporary diagnosis and management of the patient with type 2 diabetes. 2008: 72–73
- Pennsylvania, USA.
- Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analogue glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49: 2142–2148.
- Owens DR, Zinman B, Bolli GB. Insulins today and beyond. Lancet 2001; 358: 1374.
- Yki-Jarvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001; 24: 758–767.
- Havelund S, Plum A, Ribel U, et al. The mechanism of protraction of insulin detemir, a long-acting acylated analogue of human insulin. Pharma Res 2004; 21: 1498–1504.
- Rosensock J, Schwartz SL, Clark CM, et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine and NPH Insulin. Diabetes Care 2001; 24: 631–636.
- Plank J, Siebenhofer A, Berghold A, et al. Systematic review and mata-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med 2005; 165: 1337–1344.
- Hirsch IB. Insulin analogues. N Engl J Med 2005; 352: 174–183.
- Howey DC, Bowsher RR, Brunelle RL, et al. [Lys(B28), Pro(B29)-human insulin. A rapidly absorbed analogue of human insulin. Diabetes 1994; 43: 396–402.
- Turner HE, Mathews DR. The use of fixed-mixture insulins in clinical practice. Eur J Clin Phamacol 2000; 56: 19–25.
- Cooppan R. Design and management of insulin therapy: Integrating the new treatment tools. Medscape Diabetes & Endocrinology 2007.